Search results
Showing 1151 to 1200 of 2065 results for work
Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]
Discontinued Reference number: GID-TA11257
Discontinued Reference number: GID-HST10033
In development Reference number: GID-TA11627 Expected publication date: TBC
In development Reference number: GID-TA11697 Expected publication date: TBC
Discontinued Reference number: GID-TA10109
Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]
Discontinued Reference number: GID-TA10546
In development Reference number: GID-TA11274 Expected publication date: TBC
Discontinued Reference number: GID-TAG421
Discontinued Reference number: GID-TA10028
In development Reference number: GID-TA11327 Expected publication date: TBC
In development Reference number: GID-TA11831 Expected publication date: TBC
In development Reference number: GID-TA11251 Expected publication date: TBC
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]
In development Reference number: GID-TA11634 Expected publication date: TBC
In development Reference number: GID-TA11588 Expected publication date: TBC
In development Reference number: GID-TA11556 Expected publication date: TBC
In development Reference number: GID-TA11771 Expected publication date: TBC
Discontinued Reference number: GID-TA10395
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]
In development Reference number: GID-TA11272 Expected publication date: TBC
In development Reference number: GID-TA11372 Expected publication date: TBC
In development Reference number: GID-TA11709 Expected publication date: TBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]
In development Reference number: GID-TA11781 Expected publication date: TBC
Discontinued Reference number: GID-TA10271
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .
This quality standard covers preventing and treating surgical site infections. It covers adults, young people and children having a surgical procedure that involves a cut to the skin in all healthcare settings. It describes high-quality care in priority areas for improvement.
View quality statements for QS49Show all sections
Sections for QS49
- Quality statements
- Quality statement 1: Personal preparation for surgery
- Quality statement 2: Antibiotic prophylaxis
- Quality statement 3: Patient temperature
- Quality statement 4: Intraoperative staff practices
- Quality statement 5: Information and advice on wound care
- Quality statement 6: Treatment of surgical site infection
- Quality statement 7: Surveillance
This quality standard covers managing faecal (bowel) incontinence in adults (aged 18 and over) in the community (at home and in care homes) and in all hospital departments. It includes assessment of bowel control problems, advice and support, and treatment options. It describes high-quality care in priority areas for improvement.
View quality statements for QS54Show all sections
This quality standard covers identifying and supporting adults and young people (aged 10 and over) who may have an alcohol-use disorder and caring for people with alcohol-related health problems, as well as support for their families and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS11Show all sections
Sections for QS11
- Quality statements
- Quality statement 1: Use of validated alcohol questionnaires
- Quality statement 2: Community support networks and self-help groups
- Quality statement 3: Triage assessment in specialist alcohol services
- Quality statement 4: Acute alcohol withdrawal
- Quality statement 5: Interventions to prevent relapse after unplanned withdrawal from alcohol in hospital
- Update information
- About this quality standard
This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.
View quality statements for QS180Show all sections
Sections for QS180
- Quality statements
- Quality statement 1: Referral – chronic open angle glaucoma and related conditions
- Quality statement 2: Referral for cataract surgery
- Quality statement 3: Treatment – late age-related macular degeneration (wet active)
- Quality statement 4: Monitoring late age-related macular degeneration (wet active)
- Quality statement 5: Reassessment – chronic open angle glaucoma or related conditions
- Quality statement 6: Certificate of vision impairment
- Update information
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
In development Reference number: GID-TA11010 Expected publication date: TBC
Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]
Discontinued Reference number: GID-TAG408
Discontinued Reference number: GID-TAG423
In development Reference number: GID-TA11273 Expected publication date: TBC
For which people with impetigo are antiseptics as effective as antibiotics?
A faster recovery is also likely to mean less time off school, nursery or work. It was not clear in the evidence reviewed if impetigo...
Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562]
Discontinued Reference number: GID-TA10443
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701
In development Reference number: GID-TA11157 Expected publication date: TBC
Discontinued Reference number: GID-TAG400
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312
In development Reference number: GID-TA11329 Expected publication date: TBC
Discontinued Reference number: GID-TA10168
In development Reference number: GID-TA11367 Expected publication date: TBC
In development Reference number: GID-TA11301 Expected publication date: TBC
In development Reference number: GID-TA11475 Expected publication date: TBC
In development Reference number: GID-TA11589 Expected publication date: TBC
In development Reference number: GID-TA11449 Expected publication date: TBC
Newly recommended CBT therapies could help children and young people deal with anxiety
NICE conditionally recommends digital cognitive behaviour therapies (CBT) for use in the NHS to help children and young people with symptoms of mild to moderate anxiety
Hundreds could benefit from life saving blood cancer treatment recommended by NICE
People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed by a British spinout company.
Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.
Discontinued Reference number: GID-TA11655
Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]
In development Reference number: GID-TA11647 Expected publication date: TBC
Nitazoxanide for treating the common cold in people 12 years and over [ID4049]
In development Reference number: GID-TA11128 Expected publication date: TBC
In development Reference number: GID-TA11645 Expected publication date: TBC
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]
In development Reference number: GID-TA11664 Expected publication date: TBC